Disease duration

Category

1 (0 - 5 years)

2 (6 - 7 years)

3 (8 - 11 years)

4 (≥12 years)

p

Age, median (min-max)

70 (48 - 87)

70 (46 - 88)

67 (47 - 82)

73 (56 - 87)

0.540^b

Sex, n (male)

43 (21)

51 (31)

51 (25)

45 (25)

0.583^b

Levodopa equivalent dose (mg), median (min-max)

600 (0 - 1500)

700 (300 - 1500)

800 (150 - 1650)

750 (375 - 2100)

0.078^a

Levodopa dose times/day, median (min-max)

4 (0 - 8)

5 (3 - 10)

5 (3 - 8)

5 (3 - 10)

0.006*^b

Extra anti-Parkinson medication use, n (%)

23 (53.5%)

33 (64.7%)

39 (76.5%)

35 (77.8%)

0.044*^b

Use of walking aid, n (%)

7 (16.3%)

8 (15.7%)

13 (25.5%)

18 (40.0%)

0.022*^b

Bradykinesia, median (min-max)

26.40 (11.30 - 42.60)

24.90 (15.90 - 43.70)

25.30 (12.60 - 45.30)

24.70 (13.70 - 51.95)

0.877^a

Dyskinesia, median (min-max)

1.10 (0.20 - 26.85)

2.20 (0.10 - 27.00)

2.40 (0.10 - 25.80)

2.10 (0.10 - 31.90)

0.094^a

Fluctuation score, median (min-max)

8.00 (4.10 - 25.10)

9.20 (4.50 - 25.40)

9.30 (5.40 - 12.30)

9.10 (4.40 - 22.80)

0.050*^a